Keep Current with the Latest in Cell Biology Research
Block title
HIV Immune Evasin Nef Enhances Allogeneic CAR T Cell Potency
[Nature] To devise a strategy to protect allogeneic CAR T cells from host immune cells, researchers turned to lymphotropic viruses that have evolved integrated mechanisms for the immune escape of virus-infected lymphocytes.
Shigella Infection Is Facilitated by Interaction of Human Enteric α-Defensin 5 with Colonic Epithelial Receptor P2Y11
[Nature Microbiology] Scientists showed that HD5 induced abundant filopodial extensions in epithelial cells that captured Shigella, a major human enteroinvasive pathogen that was able to exploit these filopodia for invasion, revealing a mechanism for HD5-augmented bacterial invasion.
A New Method for Detecting Mixed Mycobacterium tuberculosis Infection and Reconstructing Constituent Strains Provides Insights into Transmission
[Genome Medicine] Scientists presented MixInfect2, a new tool to accurately detect mixed samples from Mycobacterium tuberculosis short-read whole genome sequence data.
Decreased SynMuv B Gene Activity in Response to Viral Infection Leads to Activation of the Antiviral RNAi Pathway in C. elegans
[PLOS Biology] Investigators showed that mRNAs highly induced in synMuv B mutants were congruent with those induced by Orsay RNA virus infection, suggesting that the enhanced RNAi of synMuv B mutants may also be triggered by down-regulation of synMuvB gene activity in an Orsay virus infection of wild type.
Diversifying T Cell Responses: Safeguarding Against Pandemic Influenza with Mosaic Nucleoprotein
[Journal of Virology] The authors hypothesized that diversifying T-cell responses, particularly targeting conserved viral proteins such as the influenza A virus (IAV) nucleoprotein, could protect against both epidemic and pandemic IAV strains.
Prolonged Exposure to Heat Enhances Mosquito Tolerance to Viral Infection
[Communications Biology] Investigators highlighted the importance of considering fluctuations in vector immunity in relation to the length of a thermal challenge to understand natural variation in vector response to viruses and frame realistic transmission models.
Differential B Cell-Mediated Immune Response during Plasmodium yoelii Infection in Mice
[Acta Tropica] Researchers investigated the modulation of different splenic subsets of B cells during Plasmodium yoelii infection. Balb/c mice infected with each Plasmodium yoelii XL and XNL parasite were used for phenotypic characterization of splenic B cell subsets through flow cytometry.
Plasma Proteomic Evidence for Increased β-Amyloid Pathology after SARS-CoV-2 Infection
[Nature Medicine] Researchers measured plasma biomarkers linked to Alzheimer’s disease pathology in the UK Biobank before and after serology-confirmed SARS-CoV-2 infections.
Induction of the Inflammasome by the SARS-CoV-2 Accessory Protein ORF9b, Abrogated by Small-Molecule ORF9b Homodimerization Inhibitors
[Journal of Medical Virology] Investigators showed that the SARS-CoV-2 accessory protein, ORF9b, but not other SARS-CoV-2 accessory proteins, strongly activated inflammasome-dependent caspase-1 in A549 lung carcinoma cells and THP-1 monocyte-macrophage cells.
Multicentre Case-Control Study on the Association Between COVID-19 Vaccines and Neurological Disorders (COVIVAX)
[Scientific Reports] The COVIVAX study assessed the association between COVID-19 vaccination and the risk of common neurological disorders in a multicenter case-control design.
Malaria: Factors Affecting Disease Severity, Immune Evasion Mechanisms, and Reversal of Immune Inhibition to Enhance Vaccine Efficacy
[PLOS Pathogens] The authors review the factors affecting the disease severity, the genetics of host–parasite interaction, immune evasion mechanisms, and approaches potentially to improve host immune response for vaccine development.
Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase III BREAKWATER Trial
[Pfizer, Inc.] Pfizer, Inc. announced positive topline results from the progression-free survival analysis of the Phase III BREAKWATER study of BRAFTOVI® in combination with cetuximab and mFOLFOX6 in patients with metastatic colorectal cancer harboring a BRAF V600E mutation.